Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury

<p dir="ltr">Bleomycin‐induced lung injury (BILI) is a well‐recognised but potentially life‐threatening complication of ABVD chemotherapy (adriamycin, bleomycin, vinblastine and dacarbazine), often requiring prompt diagnosis and intervention. We present a case of a 43‐year‐old female...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Aasir M. Suliman (14150217) (author)
مؤلفون آخرون: Irfan Ul Haq (9853260) (author), Khalid Albsheer (21767534) (author), Mohamed Elgara (9538557) (author)
منشور في: 2025
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513531581300736
author Aasir M. Suliman (14150217)
author2 Irfan Ul Haq (9853260)
Khalid Albsheer (21767534)
Mohamed Elgara (9538557)
author2_role author
author
author
author_facet Aasir M. Suliman (14150217)
Irfan Ul Haq (9853260)
Khalid Albsheer (21767534)
Mohamed Elgara (9538557)
author_role author
dc.creator.none.fl_str_mv Aasir M. Suliman (14150217)
Irfan Ul Haq (9853260)
Khalid Albsheer (21767534)
Mohamed Elgara (9538557)
dc.date.none.fl_str_mv 2025-07-14T09:00:00Z
dc.identifier.none.fl_str_mv 10.1002/rcr2.70228
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Rituximab_and_Pirfenidone_in_the_Treatment_of_Steroid_Refractory_Bleomycin_Lung_Injury/30860315
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Clinical sciences
Oncology and carcinogenesis
bleomycin
lung injury
pirfenidone
pneumonitis
rituximab
dc.title.none.fl_str_mv Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <p dir="ltr">Bleomycin‐induced lung injury (BILI) is a well‐recognised but potentially life‐threatening complication of ABVD chemotherapy (adriamycin, bleomycin, vinblastine and dacarbazine), often requiring prompt diagnosis and intervention. We present a case of a 43‐year‐old female with Hodgkin's lymphoma who developed progressive respiratory symptoms following her fourth cycle of ABVD. A broad infectious and autoimmune workup was unremarkable, and chest imaging was consistent with interstitial lung disease. Her condition deteriorated despite empirical antibiotics and high‐dose corticosteroids. The addition of rituximab and pirfenidone led to significant clinical and radiological improvement, highlighting the potential role of these agents in managing steroid‐refractory BILI.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Respirology Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/rcr2.70228" target="_blank">https://dx.doi.org/10.1002/rcr2.70228</a></p>
eu_rights_str_mv openAccess
id Manara2_235152a3a7721bb12f83978ffe02cbff
identifier_str_mv 10.1002/rcr2.70228
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/30860315
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung InjuryAasir M. Suliman (14150217)Irfan Ul Haq (9853260)Khalid Albsheer (21767534)Mohamed Elgara (9538557)Biomedical and clinical sciencesClinical sciencesOncology and carcinogenesisbleomycinlung injurypirfenidonepneumonitisrituximab<p dir="ltr">Bleomycin‐induced lung injury (BILI) is a well‐recognised but potentially life‐threatening complication of ABVD chemotherapy (adriamycin, bleomycin, vinblastine and dacarbazine), often requiring prompt diagnosis and intervention. We present a case of a 43‐year‐old female with Hodgkin's lymphoma who developed progressive respiratory symptoms following her fourth cycle of ABVD. A broad infectious and autoimmune workup was unremarkable, and chest imaging was consistent with interstitial lung disease. Her condition deteriorated despite empirical antibiotics and high‐dose corticosteroids. The addition of rituximab and pirfenidone led to significant clinical and radiological improvement, highlighting the potential role of these agents in managing steroid‐refractory BILI.</p><h2 dir="ltr">Other Information</h2><p dir="ltr">Published in: Respirology Case Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/rcr2.70228" target="_blank">https://dx.doi.org/10.1002/rcr2.70228</a></p>2025-07-14T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/rcr2.70228https://figshare.com/articles/journal_contribution/Rituximab_and_Pirfenidone_in_the_Treatment_of_Steroid_Refractory_Bleomycin_Lung_Injury/30860315CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/308603152025-07-14T09:00:00Z
spellingShingle Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
Aasir M. Suliman (14150217)
Biomedical and clinical sciences
Clinical sciences
Oncology and carcinogenesis
bleomycin
lung injury
pirfenidone
pneumonitis
rituximab
status_str publishedVersion
title Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
title_full Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
title_fullStr Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
title_full_unstemmed Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
title_short Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
title_sort Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
topic Biomedical and clinical sciences
Clinical sciences
Oncology and carcinogenesis
bleomycin
lung injury
pirfenidone
pneumonitis
rituximab